Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Korean Journal of MedicineOpen Access

Optimal Choice of Biologics and Small Molecules for Treating Women of Childbearing Age with Inflammatory Bowel Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

ESEun Mi Song

Discussion

Loading...

Member takes

Overview

Findings indicate biologics are safe during pregnancy in women with IBD, suggesting caution with small molecules.

Key Points

  • To evaluate the safety of biologic and small molecule therapies in pregnant women with inflammatory bowel disease (IBD).
  • Assessment of anti-tumor necrosis factor agents and newer biologics' safety during pregnancy.
  • Review of cohort studies and meta-analyses concerning pregnancy outcomes.
  • Consultation of international guidelines for IBD treatment in pregnant women.
  • Biologics, especially anti-TNF agents, show no significant adverse pregnancy outcomes.
  • Newer biologics have safety profiles similar to anti-TNF but require more research.
  • Small molecules have potential risks, leading to guidelines recommending their avoidance during pregnancy.

Cite This Study

Eun Mi Song (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e37ehttps://doi.org/10.3904/kjm.2025.100.6.269
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P0796Safety of advanced therapies in pregnant women with Inflammatory Bowel Disease: a systematic review and network meta-analysis2026
  2. 2Management of Pregnancy in Women with Inflammatory Bowel Disease: Positioning Janus Kinase Inhibitors Within Current Evidence2026
  3. 3Where do novel small molecules fit in the IBD treatment pathway for women of childbearing age?2025
  4. 4Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis2026
  5. 5A247 THE IMPACT OF BIOLOGICS ON MATERNAL AND NEONATAL OUTCOMES IN PREGNANT PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND THEIR ASSOCIATION WITH THERAPEUTIC DRUG LEVELS2024